Omrix Biopharmaceuticals Announces First Quarter 2008 Financial Results Date and...

Omrix Biopharmaceuticals Announces First Quarter 2008 Financial Results Date and Conference Call

NEW YORK--(Business Wire)--
OMRIX Biopharmaceuticals, Inc. ("OMRIX" or the "Company") (NASDAQ:
OMRI), a fully-integrated biopharmaceutical company that develops and
markets biosurgical and immunotherapy products, announced today that
it will announce financial results for the first quarter ended March
31, 2008 before the opening of the U.S. financial markets on Friday,
May 9, 2008. An accompanying conference call to discuss the results
will be held the same day at 8:00 am ET; 5:00 a.m. PT.

To access the live telephonic broadcast, U.S. callers should dial
(888) 396-2369; international callers may dial (617) 847.8710 and
provide confirmation code 27799085. A live audio webcast of the call
will be available via the Investor Relations' section of the Company's
website at www.omrix.com. Participants are urged to log on to the
website 15 minutes prior to the scheduled start time to download and
install any necessary software.

An audio replay of the conference call will be available from
10:00 a.m. ET on Friday, May 9, 2008 through Friday, May 16, 2008 by
dialing (888) 286-8010 from the U.S. or (617) 801-6888 when calling
internationally, and entering confirmation code 35456946. The audio
webcast will be available on the company's website, www.omrix.com, for
30 days. The financial results press release will also be accessible
on the company's website at www.omrix.com.

About Omrix Biopharmaceuticals, Inc.

Omrix is a fully integrated biopharmaceutical company that
develops, manufactures and markets protein-based biosurgery and
passive immunotherapy products. Omrix' biosurgery product line
includes products and product candidates that are used for the control
of bleeding, or hemostasis, and other surgical applications. The
Company's passive immunotherapy product line includes antibody-rich
products and product candidates for the treatment of immune
deficiencies, infectious diseases and potential biodefense
applications. For more information, please visit www.omrix.com.

Safe Harbor Statement

This news release contains forward-looking statements.
Forward-looking statements provide the Company's current expectations
or forecasts of future events. Forward-looking statements include
statements about the Company's expectations, beliefs, plans,
objectives, intentions, assumptions and other statements that are not
historical facts. Forward-looking statements are subject to known and
unknown risks and uncertainties and are based on potentially
inaccurate assumptions that could cause actual results to differ
materially from those expected or implied by the forward-looking
statements. The Company's actual results could differ materially from
those anticipated in forward-looking statements for many reasons,
including the factors described in the Company's filings with the
Securities and Exchange Commission (SEC), including sections entitled
"Risk Factors" and "Management's Discussion and Analysis of Financial
Condition and Results of Operations" in the Company's Form 10-K as
filed with the SEC on March 17, 2008, and the Company's most recent
quarterly reports on Form 10-Q and its current reports on Form 8-K.
Unless required by law, the Company undertakes no obligation to
publicly update or revise any forward-looking statement to reflect
circumstances or events after the date of this news release.

Omrix Biopharmaceuticals, Inc.
Francesca M. DeMartino, 212-887-6510
Senior Director, Investor Relations
francesca.demartino@omrix.com

Copyright Business Wire 2008